Humacyte (HUMA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Humacyte

NasdaqGS•Healthcare•Biotechnology

$0.59+0.01(0.02%)After hours

Market Cap

$134.65M

P/S

63.5x

P/B

4.3x

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

How this company scores

AverageMetricSide Score: 45/100

Strongest: Balance Sheet & Red Flags (17/25); weakest: Profitability (4/25).

Profitability4/25

Growth16/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality8/25

Strengths

Growing revenueImproving leverageConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 57.8x5y range 57.8x – 57.8x

P/S · 63.5x5y range 56.4x – 3107.2x

Currently below its 10-quarter median.

P/B · 4.3x5y range 1.9x – 80.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $134.65M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.12M
Q. Revenue: $406,000
TTM EBITDA: $-105.80M
TTM Op. Income: $-111.16M
Q. Op. Income: $-27.00M
TTM Net Income: $-96.73M
Q. Net Income: $-36.80M
EPS: $-0.16
Shares Out.: $234.18M

$2.12M in TTM revenue grew 159.3% YoY, reaching $406,000 last quarter. TTM EBITDA of $-105.80M and TTM operating income of $-111.16M show growth is flowing through to the bottom line. However, net income is negative at $96.73M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 159% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -6320.0%
Op. Margin: -6649.3%
Net Margin: -9064.5%

Op. margin of -6649.3% is up 3226.8% YoY — cost efficiency is improving. Net margin at -9064.5% Over the past year, operating margin is up 33% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 63.5x
P/B Ratio: 4.3x

P/S of 63.5x and P/B of 4.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $138.09M
Cash: $79.90M
Long-Term Debt: $36.32M
Book Value: $31.26M
D/E Ratio: 1.2
Debt/EBITDA: N/A

With $138.09M in assets and $36.32M in long-term debt, D/E is 1.2and book value is $31.26M — moderate leverage. Across the last 5 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-22.06M
TTM Free Cash Flow: $-97.56M
FCF Margin: -4599.7%
FCF / Net Income: 1.0

TTM FCF of $-97.56M on $-22.06M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.